Abstract
The hypolipidemic effect of alfibrate has been studied in normocholesterolemic rats with clofibrate as a reference. At the dosage of 150 mg/kg, 29% increase of liver weight was observed in the alfibrate group and 87% increase in the clofibrate group. Daily administration of alfibrate (150 mg/kg) produced a significant decrease in serum cholesterol (5%) and triglycerides (15%), and liver cholesterol (12%) and triglycerides (23%) with no change in phospholipids and free fatty acids. Like clofibrate, alfibrate exerted a greater effect on lowering the triglyceride level than cholesterol in normocholesterolemic rats. The liver glycogen concentration and glucose tolerance in the alfibrate group were similar to that of control.
